Ehlers-Danlos Syndrome Treatment and Management

Ehlers-Danlos syndrome has no cure, and treatment revolves around managing symptoms across multiple body systems rather than correcting the underlying connective tissue defect. Because the 2017 international classification recognizes 13 distinct subtypes, each with its own set of complications, the treatment path for one person with EDS can look nothing like another’s. The hypermobile type (hEDS), the most common form, is treated primarily through physical rehabilitation and pain control, while the rarer vascular type (vEDS) now has medication trials showing real cardiovascular protection. What ties all EDS management together is the need for coordinated care across specialties, and the reality that most patients report their care needs are not being met.

Physical Therapy as the Foundation

If there is a single treatment that comes up across nearly every EDS subtype and guideline, it is physical therapy. A scoping review of physical therapy interventions for hEDS and generalized hypermobility spectrum disorder found that therapeutic exercise and motor-function training are effective methods for treating these patients.¹ A separate systematic review focused specifically on hEDS confirmed that physiotherapy consistently improves pain and proprioception, regardless of the specific type of intervention used.²

The proprioception piece matters more than it might sound. People with EDS often have a poor sense of where their joints are in space, which contributes to repeated subluxations and injuries. Strengthening the muscles around unstable joints gives the body a kind of external scaffolding that the loose connective tissue cannot provide on its own. But the approach has to be careful. High-impact or high-resistance exercises can do more harm than good, and many physical therapists who are not experienced with EDS will push patients too hard or prescribe the wrong type of movement. The emphasis is on low-load, controlled, progressive strengthening and on proprioceptive training that teaches the body to recognize and avoid dangerous joint positions.

Orthotics and Bracing

Braces, splints, and custom orthotics fill the gap between what physical therapy can achieve and what daily life demands. A pilot study of custom foot orthoses in EDS patients found meaningful reductions in foot pain and disability after three months of use, with half the participants seeing their foot function index drop by 12 points or more.³ Custom knee orthoses have also been studied. One case report documented a patient with classical EDS who showed a roughly 22% improvement in a timed walking test and more than doubled her mobility score over 15 weeks with bilateral custom knee braces.⁴

Ring splints for finger hypermobility, ankle braces, wrist supports, and compression garments are all commonly used depending on where the instability is worst. The goal is not to immobilize a joint permanently but to provide enough external stability that the person can use the joint without it slipping out of place. Over-bracing carries its own risk: muscles that are never challenged get weaker, which can make the underlying instability worse over time. Finding the right balance between support and strengthening is something that usually requires a therapist familiar with hypermobility disorders.

Pain Management

Chronic pain is one of the most debilitating and difficult-to-treat features of EDS, particularly in the hypermobile type. The pain involves both tissue-level damage (from repeated joint injuries and microtrauma) and nervous-system sensitization, where the pain pathways themselves become overactive. A comprehensive approach typically combines non-opioid medications, physical therapy, and psychological support.⁵

Traditional medications and surgery have historically shown low effectiveness in EDS pain. Newer approaches that have shown more promise for both reducing pain and improving quality of life include transcutaneous electrical nerve stimulation (TENS), trigger-point injections, low-dose naltrexone, and laser therapy, all used alongside physical and occupational therapy.⁶ Opioids are used cautiously in this population because of connective tissue vulnerabilities and the risk of side effects compounding existing problems like gastrointestinal dysmotility.⁷

Many patients also cycle through anti-inflammatory medications, muscle relaxants, and medications originally designed for nerve pain. There is no single drug that works reliably for EDS pain, which is part of why the condition is so frustrating to manage. What works for one person may be useless for another, and the process of finding an effective combination often takes years.

Managing Autonomic Dysfunction and POTS

A large proportion of people with hEDS experience cardiovascular autonomic dysfunction, which can show up as dizziness upon standing, rapid heart rate, fainting, or exercise intolerance. The most well-known form is postural orthostatic tachycardia syndrome (POTS). First-line treatment is non-pharmacological: education about triggers, staying hydrated, increasing salt intake, wearing compression garments, and building cardiovascular fitness through graded exercise programs.⁸

When those measures are not enough, medications can help. Drug treatments for autonomic dysfunction in hEDS are supported by observational data and short-term physiological studies, though randomized controlled trials remain limited. Pharmacologic therapy is typically reserved for patients with moderate to severe impairment who have not responded to conservative measures.⁹ Common medications include fludrocortisone to expand blood volume, midodrine to constrict blood vessels, and beta-blockers or ivabradine to manage heart rate. The response varies widely from patient to patient.

Gastrointestinal Symptoms

Gut problems are common enough in hEDS that the American Gastroenterological Association published a clinical practice update specifically addressing them. The guidance recommends focusing treatment on the most prominent GI symptoms and any abnormal test results, while also addressing any symptoms attributable to POTS or mast cell activation syndrome. Standard treatments for functional GI disorders and motility problems apply, but with the addition of multidisciplinary care involving cardiology, rheumatology, dietetics, and psychology as needed.¹⁰

Dietary modifications play a real role. A gastroparesis-friendly diet (small meals, low-fiber, finely processed foods) and various elimination diets such as low-FODMAP, gluten-free, dairy-free, or low-histamine diets can improve symptoms for some patients.¹¹ One area where clinicians are growing more cautious is the escalation to tube feeding or intravenous nutrition. Emerging data suggest that enteral and parenteral nutrition are frequently started without adequate trials of oral strategies and behavioral interventions, and that once started, they are hard to scale back.¹² Current expert opinion favors exhausting conservative dietary and behavioral approaches before moving to non-oral nutrition support.

Mast Cell Activation Syndrome

MCAS shows up frequently alongside hEDS, causing symptoms like flushing, hives, abdominal cramping, and anaphylaxis-like reactions. There is no cure for mast-cell-related disorders, so treatment focuses on controlling the chemical mediators that mast cells release. The standard approach includes antihistamines (both H1 and H2 blockers), leukotriene antagonists, and in some cases omalizumab. One caveat specific to EDS: corticosteroids should generally be avoided, since they can further weaken already fragile connective tissue.¹³

Trigger avoidance is another major piece. Patients may react to temperature changes, ultraviolet radiation, common allergens, and certain foods. Keeping a trigger diary and working with an allergist or immunologist who understands the EDS overlap can make a real difference in symptom control.

Vascular EDS and Cardiovascular Protection

Vascular EDS is the subtype that carries the highest risk of life-threatening events, including arterial rupture and organ perforation. This subtype has its own targeted pharmacological interventions, which is unusual in the EDS landscape. A landmark trial found that the beta-blocker celiprolol reduced major cardiovascular events: about 20% of patients on celiprolol reached a primary endpoint compared with 50% of controls.¹⁴ Animal-model research supports this, showing that celiprolol significantly increases aortic rupture resistance, while the commonly used blood-pressure medication losartan does not, even after extended treatment periods.¹⁵

More recently, a trial of the angiotensin receptor blocker irbesartan added on top of celiprolol showed further benefit. Among patients already taking celiprolol, those who received irbesartan had a primary composite outcome rate of about 28%, compared with roughly 54% in the placebo group. The risk of recurrent arterial events dropped significantly, and progression of arterial lesions slowed at all sites measured.¹⁶ This combination represents one of the few places in EDS treatment where randomized trial data point clearly toward a specific drug regimen. Celiprolol is not available in every country, which creates access problems for some patients with vEDS.

Cardiovascular surveillance practices also vary by subtype. In one study, cardiovascular complications occurred in half of vEDS patients, though echocardiography was normal in all of them, suggesting imaging alone may miss the most dangerous problems in that subtype. Aortic dilation was common in classical EDS but absent in hEDS.¹⁷ This is a reminder that surveillance protocols need to be matched to the specific subtype rather than applied broadly.

Surgical Considerations and Tissue Fragility

Surgery in EDS carries specific risks that surgeons outside specialized centers may not anticipate. Three core problems arise from the connective tissue defect: wound breakdown because tissue lacks normal strength, increased bleeding from blood vessel fragility, and delayed wound healing. Patients with EDS who undergo surgery need an experienced surgical team and longer postoperative monitoring than typical patients.¹⁸

When wounds do become complex, newer approaches are being explored. One case report described a patient with vEDS whose large abdominal wound was successfully treated with a split-thickness skin graft combined with an autologous skin-cell harvesting device, resulting in excellent graft adherence at ten months with no complications.¹⁹ Another case trialed high-dose intravenous vitamin C alongside mesenchymal stromal cells for a complex abdominal wound in vEDS and achieved a 94% reduction in the wound bed.²⁰ These are single cases, not established protocols, but they point toward creative solutions for a real clinical problem.

Neurosurgical Interventions

Some EDS patients develop craniocervical instability (CCI), where the junction between the skull and upper spine becomes pathologically loose, or Chiari malformation, where brain tissue herniates through the base of the skull. These can cause disabling headaches, neck pain, difficulty swallowing, weakness, and neurological deficits. An outcomes analysis of 53 consecutive EDS patients who underwent occipitocervical fusion for CCI found significant improvement in headache and neck pain, decreased use of pain medication, and improved functional performance scores.²¹

A descriptive case series of 67 EDS patients who underwent various neurosurgical procedures, including suboccipital decompression, cervical fusion, and tethered cord release, reported that the vast majority experienced subjective symptomatic relief.²² Different fixation techniques for craniocervical fusion appear to produce similar outcomes.²³ These surgeries are not minor undertakings and carry real risks in patients whose tissue heals poorly, so they are reserved for cases where conservative management has failed and neurological function is deteriorating.

The Psychological Side

Living with a condition that causes chronic pain, frequent injuries, and skepticism from healthcare providers takes a serious toll on mental health. Anxiety and depression are common in EDS. Expert consensus recommends that psychiatric and psychological approaches be part of the management plan, not as an afterthought but as an integral component, including psychotherapy, appropriate medication, and psychological rehabilitation alongside physiotherapy.²⁴

One program that specifically targeted kinesiophobia, the fear of movement that develops when movement causes pain and injury, showed significant reductions in that fear along with improvements in physical performance tasks like stair walking and balance.²⁵ This is worth highlighting because kinesiophobia creates a vicious cycle: the person avoids movement, muscles weaken, joints become less stable, and pain increases. Breaking that cycle requires addressing the psychological barrier alongside the physical one. When patients do not respond to standard physical rehabilitation, exploring psychological factors that may be working against recovery is considered an essential step.²⁶

Fatigue and Sleep

Fatigue in EDS is not simply “being tired.” It results from a convergence of factors: muscle weakness from deconditioning, respiratory insufficiency, unrefreshing sleep, autonomic dysfunction, intestinal malabsorption, depression and anxiety, and sometimes overuse of pain medications.²⁷ Because the causes are so varied, effective management requires investigating which factors are contributing most in a given patient. Sleep studies may reveal fragmented sleep patterns; treating underlying autonomic symptoms may improve energy more than adding a stimulant would. Lifestyle modifications including pacing, structured rest, and gradual exercise progression form the foundation, but each contributing factor benefits from its own targeted intervention.

Pregnancy and Reproductive Care

Pregnancy in EDS requires careful planning, especially in the vascular subtype. A systematic review of vEDS and pregnancy found elevated risks of uterine rupture, vascular events, digestive complications, and maternal death, with the greatest danger concentrated around the time of delivery. The recommendation is to schedule cesarean delivery at 37 weeks to avoid the mechanical stress of labor.²⁸

However, a more recent retrospective cohort study painted a somewhat less alarming picture. In that cohort, no uterine ruptures or life-threatening vascular events occurred during the perinatal period, and the majority of women delivered vaginally. The authors suggested that current guidelines discouraging pregnancy in all women with vEDS may be too strict and proposed a shared decision-making approach instead.²⁹ The miscarriage rate in that study was about 19%, and miscarriages were significantly more frequent in women with a specific type of genetic variant (glycine substitution in COL3A1).³⁰

For hEDS, the challenges are different: joint laxity often worsens during pregnancy due to hormonal changes, pelvic instability becomes a major issue, and pain management options narrow because of fetal safety concerns. A scoping review combined with expert input concluded that multimodal, comprehensive, and individualized treatment strategies are required through pregnancy, birth, and the postpartum period.³¹

Why Multidisciplinary Care Matters

The multi-system nature of EDS means that a single specialist is rarely enough. A survey of EDS patients found that two-thirds said their current medical care needs were not being met, and 87% said it would be beneficial to receive care from a multidisciplinary clinic. When asked which specialties should be included, the top responses were pain management, physical and occupational therapy, rheumatology, cardiology, gastroenterology, and neurology.³²

A few dedicated programs have emerged. The GoodHope EDS Clinic in Toronto brings together experts from multiple specialties to provide coordinated care and has developed EDS-specific self-management programs drawing on exercise science, rehabilitation, and health psychology.³³ But programs like this remain the exception. Most people with EDS patch together their own care team across different practices, often traveling long distances to see specialists with relevant experience.

Pediatric Challenges

Children and adolescents with EDS face a particular problem: many of their providers have limited familiarity with the condition. A survey of pediatric healthcare providers found that only 9% were comfortable with the 2017 diagnostic criteria and only 4% were comfortable actually diagnosing EDS. While about 39% felt comfortable carrying out a treatment plan developed by a specialist, just 9% felt comfortable creating their own management plan. The most commonly cited barriers were lack of educational materials, knowledge, and confidence.³⁴ This means that even when a child receives a diagnosis and a specialist outlines a treatment plan, the local providers managing day-to-day care may struggle to implement it. For families, this translates into being their own advocates, educating their child’s care team, and often repeating the same explanations at every new appointment.

Nutritional Supplements and Vitamin C

The idea of using nutritional supplements for EDS has been around for two decades, but the evidence remains thin. A 2004 hypothesis paper proposed that a combination of supplements including vitamin C, magnesium, coenzyme Q10, glucosamine, and others might alleviate EDS symptoms, based on their known effects in other conditions.³⁵ That remains a hypothesis, not a proven treatment.

Vitamin C has stronger biological plausibility than most supplements because it is directly involved in collagen production. An older study of patients with the kyphoscoliotic type (EDS type VI, which involves deficient collagen lysyl hydroxylase) showed that high-dose oral vitamin C improved collagen hydroxylation in cell cultures and, after a year of supplementation, improved bleeding time, wound healing, and muscle strength in one patient.³⁶ That finding applies specifically to a subtype with a particular enzymatic deficiency and cannot be generalized to all forms of EDS. Still, vitamin C supplementation is widely used in the EDS community, and individual case reports continue to appear, including one where high-dose intravenous vitamin C contributed to healing a complex wound in a vEDS patient.³⁷ The honest assessment is that vitamin C supplementation at moderate doses is unlikely to cause harm, may help wound healing and collagen quality at the margins, but has not been validated in clinical trials for most EDS subtypes.